Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, including antiviral ...

Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, including antiviral drugs and monoclonal antibodies that suppress an ...

In a live virtual event, Attaya Suvannasankha, MD, discussed the MajesTEC-1 trial of teclistamab and approaches to mitigation ...

In a USC Keck School of Medicine press release, senior author Susanne Hempel, PhD, said, "The main message is, if your doctor puts you on Paxlovid, you don't have to worry about serious side effects.

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...

JERSEY CITY, N.J., April 01, 2025--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. JERSEY CITY ...

The U.S. Food and Drug Administration has designated Celltrion Inc.’s YUFLYMA (adalimumab-aaty), as an interchangeable biosimilar to Humira.